PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19164322-10 2009 At baseline, the adiponectin concentration was high in all observed subjects, and after 3 and 6 months of treatment with losartan, adiponectin levels decreased in the losartan group as compared with the amlodipine group (P < 0.01). Losartan 167-175 adiponectin, C1Q and collagen domain containing Homo sapiens 17-28 19730415-6 2009 Losartan (100 micromol/l) also increased adiponectin by 65% (P < 0.05). Losartan 0-8 adiponectin, C1Q and collagen domain containing Homo sapiens 41-52 19730415-10 2009 CONCLUSION: In this comparative model, telmisartan, and to a lesser extent, losartan, increased production and secretion of adiponectin from 3T3-L1 adipocytes compared to the other antihypertensive drugs. Losartan 76-84 adiponectin, C1Q and collagen domain containing Homo sapiens 124-135 19164322-0 2009 Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Losartan 160-168 adiponectin, C1Q and collagen domain containing Homo sapiens 0-11 19164322-10 2009 At baseline, the adiponectin concentration was high in all observed subjects, and after 3 and 6 months of treatment with losartan, adiponectin levels decreased in the losartan group as compared with the amlodipine group (P < 0.01). Losartan 167-175 adiponectin, C1Q and collagen domain containing Homo sapiens 131-142 19164322-13 2009 Declines in fasting insulin and HOMA-IR by losartan are accompanied by decreased adiponectin levels, might offer potential protection in humans. Losartan 43-51 adiponectin, C1Q and collagen domain containing Homo sapiens 81-92 18702955-0 2008 Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. Losartan 11-19 adiponectin, C1Q and collagen domain containing Homo sapiens 61-72 18702955-2 2008 We investigated long-term effects of losartan on serum concentrations of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS) by serial measurements over 6 months. Losartan 37-45 adiponectin, C1Q and collagen domain containing Homo sapiens 87-98 18702955-14 2008 In conclusion, serum total and HMW adiponectin concentrations increase after 6 months of losartan treatment in hypertensive patients, irrespective of the presence or absence of MS. Losartan 89-97 adiponectin, C1Q and collagen domain containing Homo sapiens 35-46 17157123-0 2006 The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Losartan 14-22 adiponectin, C1Q and collagen domain containing Homo sapiens 47-58 18971537-0 2008 Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Losartan 0-8 adiponectin, C1Q and collagen domain containing Homo sapiens 50-61 18971537-3 2008 Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients. Losartan 106-114 adiponectin, C1Q and collagen domain containing Homo sapiens 124-135 18971537-10 2008 Losartan treatment resulted in a significant increase in HMW-adiponectin concentrations (45.9%) and a significant decrease in HOMA-R (23.9%) and FFA concentrations (26.5%); the percent changes were greater than those induced by CCB treatment (p<0.001, p<0.05 and p<0.01, respectively). Losartan 0-8 adiponectin, C1Q and collagen domain containing Homo sapiens 61-72 18971537-11 2008 We conclude that losartan increases the serum HMW-adiponectin concentration and concurrently improves insulin sensitivity in subjects with IFG/IGT. Losartan 17-25 adiponectin, C1Q and collagen domain containing Homo sapiens 50-61 18971537-12 2008 These results suggest that losartan may prevent diabetes by increasing serum adiponectin levels. Losartan 27-35 adiponectin, C1Q and collagen domain containing Homo sapiens 77-88 16857181-7 2006 In Group B, losartan treatment significantly increased the serum concentrations of EC-SOD and adiponectin and decreased TNF-alpha and HOMA-R. Losartan 12-20 adiponectin, C1Q and collagen domain containing Homo sapiens 94-105 16857181-8 2006 CONCLUSION: Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production. Losartan 159-167 adiponectin, C1Q and collagen domain containing Homo sapiens 222-233 17157123-3 2006 The purpose of this study was to evaluate the influence of an ARB and a calcium channel blocker on serum adiponectin levels in Japanese patients with hypertension who were treated with losartan or amlodipine for 3 months. Losartan 185-193 adiponectin, C1Q and collagen domain containing Homo sapiens 105-116 17157123-13 2006 Losartan increased adiponectin concentrations (9.56 [6.75] to 10.36 [6.94] microg/mL; P = 0.038), whereas amlodipine had no significant effect (9.67 [6.62] to 10.01 [6.79] microg/mL). Losartan 0-8 adiponectin, C1Q and collagen domain containing Homo sapiens 19-30 17157123-15 2006 CONCLUSION: In this study, Japanese adults with EHT had significant increases in adiponectin after 3 months of treatment with 50 to 100 mg/d of losartan, but not with 5 to 10 mg/d of amlodipine. Losartan 144-152 adiponectin, C1Q and collagen domain containing Homo sapiens 81-92 15569835-9 2004 Combined therapy or losartan alone significantly increased plasma adiponectin levels and insulin sensitivity (determined by QUICKI) relative to baseline measurements. Losartan 20-28 adiponectin, C1Q and collagen domain containing Homo sapiens 66-77 21142812-1 2011 Losartan, an angiotensin II receptor blocker (ARB), has been reported to increase serum level of high-molecular weight (HMW) adiponectin, which has beneficial effects on insulin resistance and atherosclerosis. Losartan 0-8 adiponectin, C1Q and collagen domain containing Homo sapiens 125-136 15057675-0 2004 Increased plasma adiponectin in losartan-treated type 1 diabetic patients. Losartan 32-40 adiponectin, C1Q and collagen domain containing Homo sapiens 17-28 26921746-9 2016 A significant decrease of serum adiponectin level was observed after 4 months of treatment with losartan (8.86 +- 3.43 microg/mL for losartan group versus 10.71 +- 3.94 microg/mL for the control group; P = .04). Losartan 96-104 adiponectin, C1Q and collagen domain containing Homo sapiens 32-43 26921746-9 2016 A significant decrease of serum adiponectin level was observed after 4 months of treatment with losartan (8.86 +- 3.43 microg/mL for losartan group versus 10.71 +- 3.94 microg/mL for the control group; P = .04). Losartan 133-141 adiponectin, C1Q and collagen domain containing Homo sapiens 32-43 26921746-13 2016 The decrease in serum adiponectin level in nondiabetic patients on regular hemodialysis by losartan might offer a potential protective approach in these patients. Losartan 91-99 adiponectin, C1Q and collagen domain containing Homo sapiens 22-33 21107327-6 2011 We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Losartan 88-96 adiponectin, C1Q and collagen domain containing Homo sapiens 121-124 21107327-8 2011 In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not. Losartan 58-66 adiponectin, C1Q and collagen domain containing Homo sapiens 115-118